Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Percutaneous Transluminal Coronary Angioplasty

Percutaneous Transluminal Coronary Angioplasty

Percutaneous Transluminal Coronary Angioplasty (PTCA) is a minimally invasive procedure used to treat narrowed or blocked coronary arteries.
It involves threading a catheter with a balloon tip through the blood vessels to the site of the blockage.
The balloon is then inflated to open the artery and improve blood flow to the heart.
PTCA is a common treatment for coronary artery disease and can help reduce symptoms like chest pain and shortness of breath.
It is an effective alternative to more invasive bypass surgery in many cases.
However, the procedure does carry some risks, such as bleeding, blood clots, and damage to the artery.
Careful patient selection and experienced medical professional are crucial for optimal outcomes.

Most cited protocols related to «Percutaneous Transluminal Coronary Angioplasty»

1
Validating AMI Diagnosis Accuracy
Cited 44 times
The matching rate was presented as the number of matched cases divided by the number of cases retrieved from the DNMC (the gold standard). The validity of using the ICD-9 410.xx code to identify matched cases of AMI was assessed by calculating the positive predictive value (PPV) using medical records (of confirmed cases after review by the cardiologists) as the gold standard. The agreement rate between the two reviewers was calculated using the agreement cases divided by the total cases. In addition, we estimated the PPV of principal diagnosis, antiplatelet therapy, and cardiac procedures of confirmed AMI cases. Further, different criteria were used to evaluate sensitivity and PPV of the diagnosis code of AMI in the NHIRD, such as “principal diagnosis with antiplatelet” or “principal diagnosis with percutaneous transluminal coronary angioplasty (PTCA)”.
To ensure validity of procedures and aspirin/clopidogrel exposure, we defined sensitivity as the probability that the procedure/antiplatelet agents recorded in the medical chart (denominator) by a doctor were also recorded in the NHIRD (numerator). PPV is the conditional probability that claims of procedures/antiplatelet agents in the NHIRD (denominator) were actually present in the DNMC records (numerator). For agreement among discharge diagnoses for each AMI hospitalization, percentage of consistency between the two databases was calculated for linkage cases.
All computations and 95% confidence intervals (CIs) for binominal proportions were performed with SAS version 9.2 (SAS Institute Inc, Cary, NC, USA). This study was reviewed and approved by the Institutional Review Board of the National Cheng Kung University Medical Center (ER-95-137).
Cheng C.L., Lee C.H., Chen P.S., Li Y.H., Lin S.J, & Yang Y.H. (2014). Validation of Acute Myocardial Infarction Cases in the National Health Insurance Research Database in Taiwan. Journal of Epidemiology, 24(6), 500-507.
Full text: Click here
Publication 2014
Antiplatelet Agents Aspirin Cardiologists Clopidogrel Diagnosis Ethics Committees, Research Gold Heart Hospitalization Hypersensitivity Patient Discharge Percutaneous Transluminal Coronary Angioplasty Physicians Therapeutics
2
Cardiovascular Outcomes Monitoring Protocol
Cited 15 times
Certified staff, masked to participants’ intervention assignment, measured weight, waist circumference and blood pressure, assessed medication use, and obtained blood for analysis at the central laboratory annually.6 (link) Maximal exercise tests were performed on the full cohort prior to randomization. Submaximal exercise tests were performed on the full cohort at years 1 and 4 and on a subset at year 2.
During annual visits and 6-month phone calls, participants were queried by staff masked to treatment assignment about all medical events and hospitalizations. These queries were augmented with searches of national databases on deaths. Hospital and other records were obtained for potential cardiovascular events and adjudicated according to standard criteria by reviewers masked to intervention assignment (see Supplementary Appendix).
The primary end point was the first post-randomization occurrence of a composite cardiovascular outcome. Initially, the composite cardiovascular outcome included cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, and the anticipated maximal follow-up interval was 11.5 years. During the first two years of the trial, the primary event rate in the control group was lower than expected.9 (link) Therefore, hospitalized angina was added to the primary outcome and planned follow-up was extended to a maximum of 13.5 years. Three composite secondary cardiovascular outcomes were also examined: cardiovascular death, myocardial infarction, or stroke (the original primary outcome); death (all causes), myocardial infarction, stroke, or hospitalized angina; and death (all causes), myocardial infarction, stroke, hospitalized angina, coronary artery bypass grafting, percutaneous coronary angioplasty, hospitalization for heart failure, or peripheral vascular disease.
Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. (2013). The New England journal of medicine, 369(2), 145-154.
Publication 2013
Angina Pectoris Blood Pressure Cardiovascular System Cerebrovascular Accident Congestive Heart Failure Exercise Tests Hematologic Tests Hospitalization Myocardial Infarction Percutaneous Transluminal Coronary Angioplasty Peripheral Vascular Diseases Pharmaceutical Preparations Waist Circumference
3
Randomized Bone Marrow Cell Therapy for Myocardial Infarction
Cited 8 times
All patients provided written informed consent following broad discussions of the risks, benefits of the trial and alternatives explained by the investigative team. Race and ethnicity were documented as self-described by subjects. Demographic and clinical variables were determined by interview and the patient's medical record. Patients were randomized in a 2:1 ratio to cell therapy or placebo. All patients underwent bone marrow aspiration and intracoronary infusion of BMCs or cell-free solution (placebo). All caregivers and patients were blinded to treatment. Approximately 80–90 mls of bone marrow were aspirated from the iliac crest using standard techniques. The aspirate was processed at all sites with a closed, automated cell processing system (Sepax, Biosafe SA, Geneva, Switzerland)15 (link) to ensure a uniform cellular product. After BMC enrichment, cells were washed three times and suspended in 5% human serum albumin / saline. The composition of CD34+ and CD133+ cells was determined by fluorescent activated cell sorting. After the cells passed stipulated lot release criteria, including viability (>70%) and sterility, randomization was carried out according to the DCC. Treatment assignment was masked to all but one designated cell processing team member who was not involved in patient care. The target dose for the treatment group was 150 × 106 TNCs. Patients randomized to placebo received 5% HSA/saline to which 100 microliters of autologous blood was added to ensure that the color and consistency of the solution matched that of the BMC product.
Within 12 hours of aspiration, the BMCs or cell-free product was delivered to the infarct-related artery via a percutaneous transluminal coronary angioplasty (PTCA) catheter (Maverick, Boston Scientific Corporation, Natick, Massachusetts) using the Stop-Flow technique in six aliquots of five ml each, given over two minutes with balloon inflation at low pressures within the previously placed stent. Each infusion cycle was separated by balloon deflation and two minutes of reperfusion. All patients were treated with aspirin and 75 mg of clopidogrel in addition to guideline recommended post-MI medications.
Traverse J.H., Henry T.D., Ellis S.G., Pepine C.J., Willerson J.T., Zhao D.X., Forder J.R., Byrne B.J., Hatzopoulos A.K., Penn M.S., Perin E.C., Baran K.W., Chambers J., Lambert C., Raveendran G., Simon D.I., Vaughan D.E., Simpson L.M., Gee A.P., Taylor D.A., Cogle C.R., Thomas J.D., Silva G.V., Jorgenson B.C., Olson R.E., Bowman S., Francescon J., Geither C., Handberg E., Smith D.X., Baraniuk S., Piller L.B., Loghin C., Aguilar D., Richman S., Zierold C., Bettencourt J., Sayre S.L., Vojvodic R.W., Skarlatos S.I., Gordon D.J., Ebert R.F., Kwak M., Moyé L.A, & Simari R.D. (2011). Effect of Intracoronary Delivery of Autolologous Bone Marrow Mononuclear Cells Two to Three Weeks Following Acute Myocardial Infarction on Left-Ventricular Function: The LateTIME Randomized Trial. JAMA : the journal of the American Medical Association, 306(19), 2110-2119.
Publication 2011
Arteries Aspirin BLOOD Bone Marrow Catheters Cells Cell Therapy Clopidogrel Ethnicity Iliac Crest Infarction neuronectin Patients Percutaneous Transluminal Coronary Angioplasty Pharmaceutical Preparations Placebos Reperfusion Saline Solution Serum Albumin, Human Stents Sterility, Reproductive
4
Ascertaining Nonfatal Coronary Heart Disease
Cited 6 times
Whitehall-ascertained nonfatal coronary heart disease was based on 12-lead resting electrocardiogram (ECG) recording, coded using the Minnesota system, and on self-reported coronary heart disease that had been corroborated with information from the general practitioner or by manual retrieval of hospital records. The ascertainment included nonfatal myocardial infarction, definite angina, reported coronary artery bypass grafting, and percutaneous transluminal coronary angioplasty.7 (link)HES-ascertainment was based on data linkage to records from hospitalizations for nonfatal coronary heart disease as a primary or secondary diagnosis (defined using the International Statistical Classification of Diseases and Related Health Problems, version 9 [ICD-9] codes 410–414, ICD-10 codes I20–I25, or procedures K40–K49, K50, K75, U19), by using the NHS identification number.
The main outcome was the first incident or recurrent nonfatal coronary heart disease event after baseline. To capture both nonfatal and fatal coronary heart disease in a subsidiary analysis, records of coronary death (defined using ICD-9 codes 410–414 and ICD-10 codes I20–I25) were added to both ascertainment methods. Death records were obtained from data linkage to the Office of National Statistics death registry by using the NHS identification number, and the data included death date and the underlying cause.
Kivimäki M., Batty G.D., Singh-Manoux A., Britton A., Brunner E.J, & Shipley M.J. (2017). Validity of Cardiovascular Disease Event Ascertainment Using Linkage to UK Hospital Records. Epidemiology (Cambridge, Mass.), 28(5), 735-739.
Full text: Click here
Publication 2017
Angina Pectoris Cardiac Death Cardiac Events Coronary Arteriosclerosis Diagnosis Electrocardiography Heart Heart Diseases Hospitalization Myocardial Infarction Percutaneous Transluminal Coronary Angioplasty
5
Metabolite Profiling for Cardiovascular Risk
Cited 6 times
An overview of the study design is shown in Figure 1. This observational study examined metabolite associations with incident cardiovascular events in the population-based FINRISK study as discovery cohort. Metabolite biomarker candidates were replicated in two additional population-based cohorts. All participants provided written informed consent, and study protocols were approved by the local ethical committees. The main endpoint was the first incidence of a major cardiovascular event during follow-up, which includes fatal or nonfatal occurrence of myocardial infarction, ischemic stroke, cardiac revascularization (coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty), or unstable angina.26 (link) Individuals with prevalent CVD at enrolment were omitted from analyses.
The FINRISK 1997 study is a general population survey conducted to monitor the health of the Finnish population among persons aged 25–74 at recruitment.22 (link),26 (link),27 (link) In total, 8444 individuals were recruited from five study areas across Finland. Participants completed questionnaires on smoking status, alcohol usage, and medication. Median fasting time was 5h (interquartile range 4–6h). Serum total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides were measured with enzymatic methods. Metabolite profiling by high-throughput NMR was measured during 2012 for 7602 individuals with serum samples collected in 1997 available.22 (link) Pregnant women and persons missing risk factor information (n=83), and individuals with prevalent CVD (n=263) were excluded, leaving 7256 individuals for statistical analyses. Tracking of CVD during follow-up (1997 through December 2011) was enabled by ICD-10 diagnosis codes from the Finnish National Hospital Discharge Register and Causes-of-Death Register. These registers cover all cardiovascular events that have led either to hospitalization or death in Finland. The cardiovascular diagnoses in these registers have been validated.28 (link)Replication of biomarker associations with CVD and improvements in risk prediction were examined in two population-based studies from the UK: fasting serum samples from the Southall and Brent Revisited study (SABRE, n=2622)29 (link) and the British Women’s Heart and Health Study (BWHHS, n=3563)30 (link) were profiled by the same NMR metabolomics platform as used in FINRISK. Detailed information on the study populations is provided in the expanded methods online.
Würtz P., Havulinna A.S., Soininen P., Tynkkynen T., Prieto-Merino D., Tillin T., Ghorbani A., Artati A., Wang Q., Tiainen M., Kangas A.J., Kettunen J., Kaikkonen J., Mikkilä V., Jula A., Kähönen M., Lehtimäki T., Lawlor D.A., Gaunt T.R., Hughes A.D., Sattar N., Illig T., Adamski J., Wang T.J., Perola M., Ripatti S., Vasan R.S., Raitakari O.T., Gerszten R.E., Casas J.P., Chaturvedi N., Ala-Korpela M, & Salomaa V. (2015). Metabolite Profiling and Cardiovascular Event Risk: A Prospective Study of Three Population-Based Cohorts. Circulation, 131(9), 774-785.
Publication 2015
Angina, Unstable Biological Markers Cardiovascular System Cholesterol Coronary Artery Bypass Surgery Diagnosis DNA Replication Enzymes Ethanol Heart High Density Lipoprotein Cholesterol Hospitalization Myocardial Infarction Myocardial Revascularization Patient Discharge Percutaneous Transluminal Coronary Angioplasty Pharmaceutical Preparations Population Group Population Health Pregnant Women Serum Stroke, Ischemic Triglycerides Woman

Most recents protocols related to «Percutaneous Transluminal Coronary Angioplasty»

1
Defining Diabetic Complications: A Comprehensive Approach
Macrovascular complications are composed of cardiovascular disease, cerebrovascular disease, and peripheral arterial occlusive disease (PAOD); whereas microvascular complications comprise neuropathy, nephropathy, and retinopathy [1 (link), 2 (link)]. In this study, patients with any one of the listed conditions including coronary heart disease, myocardial ischemia and/or infarction, angina, congestive heart failure, arrhythmia, and a history of percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft surgery (CABG) were referred to have cardiovascular disease. The cerebrovascular disease is defined as a group of diseases including transient ischemic attack (TIA), ischemic stroke, and hemorrhagic stroke. PAOD is defined as a composite of following status, such as having symptom of intermittent claudication, abnormal foot assessment with reduced or absent pulse over dorsalis pedis artery and/or posterior tibial artery, and a history of percutaneous transluminal angioplasty (PTA), peripheral artery bypass surgery, or amputation. Moreover, diabetic polyneuropathy comprises patients who had neurologic symptoms or aberrant neurologic physical examinations such as decrease/loss of vibratory or pinprick sensation tested by hemi-quantified tuning fork and single-stranded nylon, respectively, on either foot. Patients with diabetic retinopathy are defined as those who had one of the following conditions including macular degeneration, non-proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), blindness, or receiving laser therapy of retina in the past. Estimated glomerular filtration rate (eGFR), expressed in ml/min/1.73 m2, was calculated using the equation from Modification of Diet in Renal Disease (MDRD) [22 (link)]. Finally, diabetic kidney disease (DKD) in this study was defined as eGFR < 60 ml/min/1.73 m2 or albuminuria defined as a spot urine albumin to creatinine ratio (UACR) ≥ 30 mg/g.
Ho L.J., Sheu W.H., Lo S.H., Yeh Y.P., Hwu C.M., Huang C.N., Hsieh C.H, & Kuo F.C. (2023). Unhealthy lifestyle associated with increased risk of macro- and micro-vascular comorbidities in patients with long-duration type 2 diabetes: results from the Taiwan Diabetes Registry. Diabetology & Metabolic Syndrome, 15, 38.
Full text: Click here
Publication 2023
Age-Related Macular Degeneration Albumins Amputation Angina Pectoris Arterial Occlusive Diseases Arteries Blindness Cardiac Arrhythmia Cardiovascular Diseases Cerebrovascular Disorders Congestive Heart Failure Coronary Arteriosclerosis Coronary Artery Bypass Surgery Creatinine Diabetic Nephropathy Diabetic Polyneuropathies Diabetic Retinopathy Dietary Modification Foot Glomerular Filtration Rate Heart Disease, Coronary Hemorrhagic Stroke Infarction Intermittent Claudication Kidney Diseases Laser Therapy Neurologic Examination Neurologic Symptoms Nylons Operative Surgical Procedures Patients Percutaneous Transluminal Angioplasty Percutaneous Transluminal Coronary Angioplasty Peripheral Vascular Diseases Pulse Rate Retina Retinal Diseases Stroke, Ischemic Tibial Arteries, Posterior Transient Ischemic Attack Urine Vibration
2
Isolated CABG Procedure Incidence Analysis
Data on patients 18 years or older with an ICD-10-CM/PCS or MS-DRG code for an isolated CABG procedure without percutaneous transluminal coronary angioplasty (DRG 233, 234, 235, 236) with an index admission between 1 January 2016 and 30 June 2020 were included in the study.
Patients were excluded if they had a CABG procedure within 90 days before their index hospitalization admission date. Patients with evidence of CABG and percutaneous transluminal coronary angioplasty or CABG and concomitant aortic valve replacement or CABG and mitral valve replacement or repair or CABG and transcatheter aortic valve replacement or implantation or CABG and cardiogenic shock were also excluded. The patient attrition flowchart with the inclusion and exclusion criteria is summarized in Figure 2.
Sosa M.P., McNicholas D.G., Bebla A.B., Emont S., Cao Z., Lipkin C., Ajmani V, & Muehrcke D.D. (2023). Ninety-day all-cause emergency room use among coronary artery bypass grafting patients associated with near-infrared fluorescence imaging: a retrospective cohort study. Annals of Medicine and Surgery, 85(2), 153-160.
Full text: Click here
Publication 2023
Coronary Artery Bypass Surgery Hospitalization Mitral Valve Ovum Implantation Patients Percutaneous Transluminal Coronary Angioplasty Shock, Cardiogenic Tooth Attrition Transcatheter Aortic Valve Replacement Valves, Aortic
3
Evaluate Mechanical Aspiration Thrombectomy in ACS
CHEETAH (A Prospective, Multicenter Study to Evaluate the Safety and Performance of the CAT RX Aspiration Catheter in Patients With a High Thrombus Burden Acute Coronary Vessel Occlusion) was a single-arm, postmarket registry study that enrolled patients from August 2019 through December 2020 at 25 hospitals across the United States and was designed to assess the feasibility of broader utilization of sustained mechanical aspiration thrombectomy. Patients were followed for 180 days or to outcome (ie, withdrawal or death), whichever occurred first. Consecutive patients presenting with acute coronary vessel occlusion and high thrombus burden who were referred for PCI were screened. Sites kept a screening log of potential study candidates with reason(s) for exclusion recorded (Table S2). The study was conducted with proper ethical oversight, and each site obtained institutional review board (Listing S1) approval prior to enrolling patients. Inclusion criteria were as follows: age ≥18 years, presenting to treating facility within 12 hours of symptom onset, coronary occlusion with high thrombus burden (Thrombolysis in Myocardial Infarction [TIMI] thrombus grade 4 or 5 on angiography after the guidewire crossed the target lesion), target lesion located in a native coronary artery, utilization of the Indigo CAT RX Aspiration System prior to PCI, and informed consent obtained from either the patient or a legally authorized representative. Due to the nature and severity of acute MI, informed consent could be obtained up to 2 calendar days postprocedure, but prior to discharge. The choice of aspiration frontline or percutaneous transluminal coronary angioplasty first was based on the operator discretion. Exclusion criteria were as follows: new onset of stroke symptoms and National Institutes of Health Stroke Scale score >2 prior to index procedure, treatment with fibrinolytic therapy for index coronary vessel occlusion, life expectancy <6 months due to any comorbidities, patient unwilling or unable to comply with protocol follow-up schedule or based on the Investigator’s judgement that the patient was not a good study candidate, participation in another investigational drug or device study that may confound the results of this study, and patient was pregnant.
Mathews S.J., Parikh S.A., Wu W., Metzger D.C., Chambers J.W., Ghali M.G., Sumners M.J., Kolski B.C., Pinto D.S, & Dohad S. (2023). Sustained Mechanical Aspiration Thrombectomy for High Thrombus Burden Coronary Vessel Occlusion: The Multicenter CHEETAH Study. Circulation. Cardiovascular Interventions, 16(2), e012433.
Publication 2023
Angiography Artery, Coronary Aspiration Thrombectomy Blood Vessel Catheters Cerebrovascular Accident Cheetahs Coronary Occlusion Coronary Vessels Dental Occlusion Ethics Committees, Research Fibrinolytic Agents Indigo Investigational New Drugs Medical Devices Myocardial Infarction Patient Discharge Patients Percutaneous Transluminal Coronary Angioplasty Safety Thrombolytic Therapy Thrombus
4
Cardiovascular Disease Onset and Mortality
The primary outcome of this study was onset of CVD, including CHD and stroke. CVD was diagnosed by cardiologists from the tertiary hospital’s clinical events committee after reviewing all medical records. CHD was defined as a fatal or nonfatal myocardial infarction, unstable angina, and coronary revascularization (coronary artery bypass grafting or percutaneous transluminal coronary angioplasty). Stroke (ischemic and hemorrhagic strokes) was defined as a rapid or sudden onset fixed neurologic deficit of at least 24h or until death (a detailed definition of CVD is provided in Supplementary Material). Inpatient medical records, outpatient interviews, and telephone interviews were used to obtain follow-up results. Deaths due to CVD are confirmed by population management consulting and hospital death certificates, and appraised by the clinical events committee at our tertiary hospital. Following the first visit, participants were followed until either a new cardiovascular disease or death occurred, whichever occurred first, or until the end of the follow-up period in January 2021.
Yang W., Cai X., Hu J., Wen W., Mulalibieke H., Yao X., Yao L., Zhu Q., Hong J., Luo Q., Liu S, & Li N. (2023). The Metabolic Score for Insulin Resistance (METS-IR) Predicts Cardiovascular Disease and Its Subtypes in Patients with Hypertension and Obstructive Sleep Apnea. Clinical Epidemiology, 15, 177-189.
Publication 2023
Angina, Unstable Cardiologists Cardiovascular Diseases Cerebrovascular Accident Heart Hemorrhagic Stroke Inpatient Myocardial Infarction Outpatients Percutaneous Transluminal Coronary Angioplasty
5
Virtual Reality in Post-Acute Sequelae of COVID-19
The study was conducted among patients with PASC who participated in inpatient pulmonary rehabilitation at the Specialist Hospital in Glucholazy (Poland). These preliminary results included 32 randomly selected patients aged 41–67 years old who met the inclusion criteria and gave written consent to participate in the study. The patients were randomized to two groups: experimental (VR group) which participated in the pulmonary rehabilitation program incorporated with VR-based features, and the control group (control group) participating in the same therapeutic elements but in a traditional manner. Randomization was performed using the Research Randomizer (ratio 1:1), a web-based service that offers instant random assignment. Sealed envelopes were used for group assignment. The inclusion criteria were: women and men aged 40–80 years and a confirmation from a primary care physician of having had COVID-19 infection. The exclusion criteria were: no consent to participate, active pneumonia diagnosed by x-ray, documented heart disease (stable or unstable), status after coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, insulin-dependent diabetes mellitus, inability to exercise independently or musculoskeletal/neurological conditions that would prevent completion of the course, lung cancer, cognitive impairment, or Mini-Mental State Examination < 24. This study implemented a randomized control trial study design, approved by Bioethical commission Opole Medical Chamber in Opole (Approval Number: No. 343, 25 November 2021), registered in ClinicalTrials.gov (NCT05244135), and carried out in accordance with the Declaration of Helsinki guidelines (22 (link)). All participants gave written informed consent.
Rutkowski S., Bogacz K., Rutkowska A., Szczegielniak J, & Casaburi R. (2023). Inpatient post-COVID-19 rehabilitation program featuring virtual reality—Preliminary results of randomized controlled trial. Frontiers in Public Health, 11, 1121554.
Full text: Click here
Publication 2023
COVID 19 Diabetes Mellitus, Insulin-Dependent Disorders, Cognitive Heart Diseases Inpatient Lung Lung Cancer Mini Mental State Examination Musculoskeletal Diseases Pancreatic Stellate Cells Patients Percutaneous Transluminal Coronary Angioplasty Pneumonia Primary Care Physicians Rehabilitation Specialists Therapeutics Woman X-Rays, Diagnostic

Top products related to «Percutaneous Transluminal Coronary Angioplasty»

1
Sphygmomanometer by Hill-Rom
Sourced in United States
The Sphygmomanometer is a medical device used to measure blood pressure. It consists of an inflatable cuff that is wrapped around the patient's arm and a gauge that displays the blood pressure reading.
2
Allprotect tissue reagent by Qiagen
Sourced in Germany, United States, United Kingdom
The Allprotect Tissue Reagent is a solution designed to stabilize and preserve RNA, DNA, and proteins in tissue samples. It is intended for use in the collection, storage, and transport of biological samples prior to analysis.
3
Wakosil 2 5c18 rs by Fujifilm
Sourced in Japan
Wakosil-II 5C18 RS is a high-performance reversed-phase HPLC column designed for the separation and analysis of a wide range of compounds. It features a silica-based stationary phase with C18 alkyl ligands, providing excellent retention and selectivity for both polar and non-polar analytes.
4
Visipaque by GE Healthcare
Sourced in Ireland, United States, Germany, United Kingdom, Norway, Italy, Denmark
Visipaque is a radiographic contrast agent used in medical imaging procedures. It contains the active ingredient iodixanol, which aids in visualizing internal structures and organs during diagnostic imaging tests.
5
Statistical package for the social sciences spss by IBM
Sourced in United States
SPSS is a software package used for statistical analysis. It is designed to manage and analyze data, with a focus on social sciences and market research. SPSS provides a range of statistical tools, including descriptive statistics, regression analysis, and data visualization.
6
Ftc 13c 15 n2 by Moravek Biochemicals
Sourced in Canada
The FTC-13C 15 N2 is a laboratory instrument designed for the detection and analysis of carbon-13 and nitrogen-15 isotopes. It provides accurate measurements of these isotopic ratios in various samples. The core function of the FTC-13C 15 N2 is to facilitate the analysis of stable isotopes for research and applications that require precise isotopic information.
7
Vhb tape by 3M
Sourced in United States
VHB tape is a high-performance, double-sided acrylic foam tape manufactured by 3M. It is designed to provide a strong, durable bond between a variety of materials, including metal, glass, plastic, and more. The tape features a viscoelastic adhesive that can accommodate surface irregularities and distribute stress evenly, making it suitable for a range of industrial and commercial applications.
8
Allprep dna rna protein mini kit by Qiagen
Sourced in Germany, United States, United Kingdom, Netherlands, Italy, Spain, Brazil, Sweden, Canada, Switzerland
The AllPrep DNA/RNA/Protein Mini Kit is a laboratory equipment product designed for the simultaneous purification of genomic DNA, total RNA, and total protein from a single sample. It provides a convenient and efficient method for extracting these biomolecules from a variety of biological sources.
9
C7 xr oct intravascular imaging system by Abbott
Sourced in United States
The C7-XR OCT Intravascular Imaging System is a medical imaging device designed for intravascular imaging. It uses optical coherence tomography (OCT) technology to capture high-resolution, cross-sectional images of the inside of blood vessels. The device is intended to provide healthcare professionals with detailed visual information about the condition of blood vessels.
10
Melanin from sepia officinalis by Merck Group
Sourced in United States
Melanin from Sepia officinalis is a natural pigment extracted from the ink sac of the cuttlefish Sepia officinalis. It is a dark, water-soluble pigment with antioxidant properties. This product is suitable for use in various laboratory applications, including research and analysis.

More about "Percutaneous Transluminal Coronary Angioplasty"

Percutaneous Transluminal Coronary Angioplasty (PTCA), also known as Percutaneous Coronary Intervention (PCI), is a minimally invasive procedure used to treat narrowed or blocked coronary arteries.
This procedure involves threading a catheter with a balloon tip through the blood vessels to the site of the blockage.
The balloon is then inflated to open the artery and improve blood flow to the heart.
PTCA is a common treatment for coronary artery disease and can help reduce symptoms like chest pain and shortness of breath.
It is an effective alternative to more invasive bypass surgery in many cases.
The procedure is typically performed under local anesthesia and sedation, using a Sphygmomanometer to monitor the patient's blood pressure.
During the procedure, the surgeon may use specialized imaging techniques like the C7-XR OCT Intravascular Imaging System to visualize the blockage and guide the placement of the balloon catheter.
To enhance the success of the procedure, healthcare providers may utilize a variety of products, such as the Allprotect Tissue Reagent to preserve the tissue sample, the Wakosil-II 5C18 RS column for chromatographic analysis, and the Visipaque contrast agent to enhance visualization of the blood vessels.
Post-procedure, the patient may undergo statistical analysis using the Statistical Package for the Social Sciences (SPSS) to evaluate the outcomes of the PTCA.
Additionally, the FTC-13C 15 N2 labeling technique may be used to study the metabolic processes in the heart following the intervention.
In some cases, the surgeon may need to use VHB tape to secure the catheter in place during the procedure.
The AllPrep DNA/RNA/Protein Mini Kit can also be useful for extracting and analyzing biological samples collected during the PTCA.
Melanin from Sepia officinalis, a natural pigment, has been studied for its potential use in cardiovascular applications, including the development of novel therapies for coronary artery disease.
Overall, Percutaneous Transluminal Coronary Angioplasty is a minimally invasive and effective treatment option for coronary artery disease, with the potential to improve patient outcomes and reduce the need for more invasive surgical interventions.